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Forbedret ultralydavbildning og konsekvenser ved alvorlige og 
mindre alvorlige utviklingsavvik hos foster 
I Norge ble rutineultralyd rundt uke 18 innført i 1986 som en del av svangerskapsomsorgen. Målet med 
undersøkelsen er terminbestemmelse, påvisning av morkakens leie og bestemmelse av antall foster. I 
tillegg gjøres en detaljert gjennomgang av fosterets anatomi. Hvis det oppdages utviklingsavvik hos 
fosteret, kan dette føre til konsekvenser for behandlingen av både foster, svangerskap og den nyfødte. I 
noen tilfeller kan ultralydfunnet føre til et ønske om å avbryte svangerskapet. Utviklingen av 
ultralydteknologien og øket kompetanse hos de som utfører ultralydundersøkelser, har medført en øket 
oppdagelse av foster med utviklingsavvik. 
 
Et mål med studien var å studere mindre utviklingsavvik som klumpfot og leppe-kjeve-ganespalte, som 
kan være alvorlige hvis de opptrer i forbindelse med kromosomfeil, syndromer ol. I tillegg ble alle med 
diagnosen Down syndrom i vår populasjon studert. Hovedmålet med studien var å se på konsekvensene 
av rutineultralyd ved 18 uker i forhold til svangerskapsavbrudd ved ultralydfunn. 
 
Det ble utført en prospektiv oppfølgningsstudie i en uselektert norsk populasjon fra 1987 til og med 
2004 med til sammen 49 314 fødsler. Studien ble delt opp i tidsperioder for å se på forandringer over 
tid når det gjaldt oppdagelsesrater, samt for å se om alvorlighetsgraden for årsaken til 
svangerskapsavbrudd hadde forandret seg over tid. 
 
I den første studien undersøkte vi alle 113 foster/barn med diagnosen klumpfot, som var blitt registrert i 
løpet av atten år. Det forelå en signifikant forbedret oppdagelsesrate av klumpfot over tid. De tre største 
gruppene av assosierte utviklingsavvik ble funnet å være syndromer og sekvenser, kromosomfeil og 
muskel-skjelettsykdommer. Vår studie viste også at det i noen tilfeller av antatt isolert klumpfot forelå 
kromosomfeil eller alvorlige syndromer som først ble oppdaget etter fødselen. 
 
I studie nummer to ble 101 registrerte fostre eller nyfødte med leppe-kjeve-ganespalte undersøkt i 
samme 18-års periode. Isolert ganespalte ble aldri påvist prenatalt. Det var en signifikant økt 
oppdagelsesraterate av både leppespalte og leppe-kjeve-ganespalte over tid. Førtitre prosent av 
foster/barn med leppe-kjeve-ganespalte og 58% med ganespalte hadde utviklingsavvik i tillegg. 
Studien viste også tilfeller av antatt isolert leppe-kjeve-ganespalte der det etter fødselen viste seg å 
foreligge alvorlige syndromer eller kromosomfeil. 
 
I den tredje studien undersøkte vi alle 88 med registrert Down syndrom over en 18-års periode. Den 
prenatale oppdagelsesraten var 43%. Fjorten prosent ble påvist ved fostervannsprøve pga. mors alder 
på 38 år og eldre, 29% ble påvist ved ultralyd. Det kunne ikke påvises forandring i oppdagelsesrate i 
18-års perioden. Studien viste at et program basert på mors alder for å påvise Down syndrom har liten 
effekt, og at ultralyd rundt uke 18 er en dårlig metode for å påvise Down syndrom. Raten av 
svangerskapsavbrudd etter påvisning av Down syndrom var uforandret i de tre periodene, rundt 84%. 
 
Den fjerde studien viste at det hadde vært utført svangerskapsavbrudd pga. utviklingsavvik i 163 
tilfeller på 15 år i populasjonen på 49 314 gravide. Det forelå en økt oppdagelsesrate av foster med 
utviklingsavvik i samme tidsperiode, men det var en signifikant nedgang av svangerskapsavbrudd. Det 
ble ikke sett noen forandring over tid i alvorlighetsgrad av diagnosene hos foster der svangerskapet ble 
avbrutt. Raten av avbrudd forårsaket av dødelige så vel som svært alvorlige sykdomstilstander var i 
første periode 90%, i andre periode 94% og i tredje periode 84%. Studien viser at det har vært mulig å 
opprettholde et tilbud til alle gravide om ultralydundersøkelse ved 18 uker uten at en fryktet økning av 
svangerskapsavbrudd har funnet sted. Fagområdet fostermedisin og den over tid oppbygde 
rådgivningen til gravide ved påviste funn, tillegges stor vekt for disse resultatene. 
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INTRODUCTION 
 
The introduction of ultrasound in obstetrics in the late 1950s was the beginning of a 
new era. In the decades that followed, improved ultrasound equipment, better skills 
and increasing knowledge have changed prenatal care. In the early 1980s it was 
controversial whether ultrasound should be used as an examination method for all 
pregnancies or whether it should be reserved for specific indications. Which 
application of ultrasound would have a positive impact on the outcome? Additionally, 
a number of ethical questions arose as a consequence of prenatal detection of 
anomalies on the background of cultural, political and economic differences in 
different countries. 
 
Ian Donald pioneered the development of ultrasound technology for clinical use and 
initiated the first clinical studies in the field of obstetrics and gynecology. In 1955 he 
started to explore pelvic tumors in vitro before he developed obstetrical ultrasound. 
His Lancet publication in 1958 was a landmark paper describing ovarian cysts, 
fibroids, ascites, abdominal carcinomatosis and various conditions related to 
pregnancy (Donald et al. 1958). The first fetal anomaly displayed by ultrasound was 
reported shortly thereafter and described a case of fetal hydrocephaly (Donald and 
Brown 1961). In 1964, Bertil Sundén from Lund in Sweden was the first to address 
the use of ultrasound in obstetrics and gynecology in a doctoral thesis. Amongst 
numerous first-time observations, he described the first anencephalic fetus (Sunden 
1964). In 1968, Stuart Campbell (Campbell 1968) introduced an improved method to 
measure the fetal biparietal diameter, today a standard measurement in fetal biometry. 
In 1972, Campbell published reports on detection of anencephaly (Campbell et al. 
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1972) and later of spina bifida (Campbell et al. 1975). The first fetal kidney anomaly 
was described by Garrett in Australia (Garrett et al. 1970). In the years that followed, 
several anomalies were detected, parallel to improvement of ultrasound technology 
(Levi et al. 1995; Levi 1997; Zimmer et al. 1997). More recent studies have pointed 
out that detection rates have increased not only because of improved technology, but 
also because of improved sonographer skills (Taipale et al. 2003; Tegnander and Eik-
Nes 2006). 
 
Development of ultrasound technology in obstetrics 
 
The increasing use of ultrasound in obstetrics raised the awareness of the efficacy of 
performing systematic fetal ultrasound examinations in every pregnancy as opposed 
to using ultrasound only when a problem was identified on the basis of classical 
clinical findings. Randomized controlled trials were carried out to investigate benefits 
of systematic use of ultrasound examination in pregnancy (Bennett et al. 1982; 
Bakketeig et al. 1984; Eik-Nes et al. 1984; Neilson et al. 1984; Waldenström et al. 
1988; Saari-Kemppainen et al. 1990; Ewigman et al. 1993; Salvesen 1993; Saari-
Kemppainen et al. 1994; Saari-Kemppainen 1995; Eik-Nes et al. 2000). 
A Cochrane review (Neilson 2004) on second trimester ultrasound examination before 
24 weeks, compared an offer of ultrasound examination to all pregnant women, with 
offering ultrasound examinations for specific indications only. The review showed 
that the main benefit of an offer to all was a more precise estimate of the gestational 
age, resulting in a 70% reduction of induction for overdue pregnancies (Eik-Nes et al. 
1984; Waldenström et al. 1988). Further advantages amongst the systematically 
examined group were earlier detection of multiple pregnancies and earlier detection of 
10 
clinically unsuspected fetal malformation at a time when termination of pregnancy 
(TOP) is possible. In the main results there were no differences in a particular clinical 
outcome, such as perinatal mortality. However, a Helsisinki trial showed a reduced 
perinatal mortality of nearly 50% due to early detection of major anomalies that led to 
termination of pregnancy (Saari-Kemppainen et al. 1990). A one stage second 
trimester ultrasound examination also demonstrated to be very cost effective, with 
significantly fewer perinatal deaths in systematically examined groups (Leivo et al. 
1996; Buechler 1998). The RADIUS trial (Ewigman et al. 1993), which was included 
in the Cochrane review, has been one of the most controversial studies because of 
their negative results in favor of offering an ultrasound examination to all pregnant 
women. The RADIUS study authors concluded that systematic use of second 
trimester ultrasound examination did not improve perinatal outcome as compared with 
the selective use of ultrasound on the basis of the clinician’s judgment. The low 
detection rate of anomalies of 17% before 24 weeks of gestation was far below 
standards and has been criticized; the poor results in the RADIUS study were most 
probably due to insufficient sonographer skills (Romero 1993; Eik-Nes et al. 2000; 
Neilson 2004). 
 
The first program using ultrasound systematically in pregnancy was initiated in 
Malmö, Sweden in 1974. A single scan was performed in pregnancy week 28 in order 
to detect twin pregnancies. Over the years, the examination was moved towards week 
17. From 1976 on, a second routine examination was included, at 32 gestational 
weeks (Grennert et al. 1978). The health authorities in Sweden have never officially 
introduced the program. However, the Malmö program was later adopted throughout 
Sweden and influenced a similar German program in 1980. 
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Germany was then the first country to officially introduce a two-stage-screening 
program to all pregnant women (Mutterschafts-Richtlinien 1980). In Norway, a 
consensus panel recommended offering one ultrasound examination at approximately 
18 gestational weeks to all pregnant women (Backe and Buhaug 1986). The 
recommendation was based on the reported decrease in post-term pregnancies, 
following the introduction of routine ultrasound (Eik-Nes et al. 1984). Moreover there 
was a need to regulate the already extensive use of ultrasound in pregnancy and to 
reduce the number of scans (Eik-Nes 1986). Following the introduction of the 
program, it was shown that the number of scans was reduced (Backe and Buhaug 
1986; Eik-Nes 1986; Backe 1997). In a number of other European countries, the 
health authorities introduced routine ultrasound examination. Iceland followed the 
Norwegian one-stage model in 1987 (Geirsson 1987) and Austria followed the 
German two-stage model in 1988. In 1995, Germany expanded the program by 
offering an early fetal scan at 10 weeks (Änderung der Mutterschafts-Richtlinien 
1995). In 1996, Switzerland introduced an early scan at 10 weeks followed by a scan 
at 18 weeks. Although not all countries have officially introduced a systematic 
program, today most countries in the industrialized world offer ultrasound 
examinations to their pregnant population (Care 1998). The major reasons for the 
systematic introduction of ultrasound are the benefits of management of pregnancy 
and fetal outcome, as well as accurate pregnancy dating and early twin detection 
(Care 1998; Neilson 2004).  
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Detection of congenital fetal anomalies 
 
Congenital anomalies are found in approximately 3% of all infants (Kalter and 
Warkany 1983; EUROCAT 1997). The reported incidence varies, depending on 
ethnicity, populations (selected or non-selected) and period of follow up. Additional 
criteria such as inclusion or exclusion of spontaneous abortions, intrauterine fetal 
deaths and terminations may affect the figures. 
 
The accuracy of ultrasound detection of fetal anomalies in high-risk populations was 
evaluated during the early 1980s in Europe by Campbell and Pearce (Campbell and 
Pearce 1983), Gembruch and Hansmann (Hansmann and Gembruch 1984) and in the 
USA by Sabbagha et al. (Sabbagha et al. 1985). 
 
Detection of congenital anomalies in large series was evaluated in the late 1970s by 
Campbell and Pearce (Campbell and Pearce 1983) and then in Sweden (Kullendorff et 
al. 1984) and in the USA (Hill et al. 1985; Li et al. 1988). Systematic routine 
ultrasound for identification of congenital anomalies was performed in strictly low-
risk pregnancies in larger populations from the late 1980s through early 1990s (Levi 
et al. 1989; Chitty et al. 1991; Saari-Kemppainen et al. 1994) .  
 
Studies have shown great variation in the detection rates of anomalies. A review of 36 
studies published between 1978-1997 (Levi 2002), showed that the sensitivity for 
prenatal detection of fetal anomalies varied from 8-90%. It is therefore understandable 
that the reliability and utility of ultrasound examination for fetal anomalies have 
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become the subject of so many controversies, and that there was hesitation in 
initiating routine ultrasound examination, instead of performing ultrasound 
examination on specific indications (Ewigman et al. 1993; Romero 1993; Eik-Nes et 
al. 2000; Neilson 2004).  
 
Most fetuses with major chromosome aberrations have structural anomalies 
(Wladimiroff 1995) which are possible to detect by ultrasound examination 
(Nicolaides et al. 1993). Although there are certain patterns of structural defects (Hill 
1996), specific fetal structural anomalies are not pathognomonic for individual 
chromosomal abnormalities. Consequently, studies have shown a huge variation in 
ultrasound detection rates from 7% to 80% of all chromosomal abnormalities (Stoll et 
al. 1991; Gagnon et al. 1992; Nicolaides 1992; Twining and Zuccollo 1993; Claussen 
et al. 1994; Den Hollander et al. 1994; Meagher et al. 1994; Hill 1996; Grandjean et 
al. 1998; Bromley et al. 2002).  
 
There is a well-known association between all trisomies and maternal age. The 
association between trisomy 21 and increased maternal age was noted in 1909 by 
Shuttleworth (Shuttleworth 1909), the risk rapidly increasing after 40 years of age. 
Due to this association, most western countries offered additional tests to rule out any 
chromosome aberrations to pregnant women over 35 years of age. Trisomy 13, 18 and 
21 account for 67% of all fetuses born with a karyotypic abnormality (Snijders et al. 
1994). 
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Detection of fetal chromosomal aberrations – especially trisomy 21 
 
In 1966, it became possible to diagnose trisomy 21 prenatally by karyotyping cultured 
amniotic fluid cells (Steele and Breg 1966; Valenti et al. 1968). Currently, both 
chorionic villus sampling (CVS) and amniocentesis (AC) are used as highly accurate 
diagnostic tests for fetal chromosomal aberrations (Hahnemann and Vejerslev 1997). 
Amniocentesis at 16 weeks is associated with a 0.5-1% risk of fetal loss (Tabor et al. 
1986; Saltvedt and Almstrom 1999). CVS performed at 11-13 weeks carries a fetal 
loss rate similar to mid-trimester amniocentesis (Smidt-Jensen et al. 1992; Kuliev et 
al. 1996). Studies of the effect of early AC performed at 10-13 weeks show an 
increased risk of fetal loss and increased risk for talipes equinovarus (CEMAT 1998). 
AC performed at 16 weeks and onwards seems to be the safest, and is therefore the 
predominant choice at our center (Tabor et al. 1986; Smidt-Jensen et al. 1992). A 
complete analysis of the fetal chromosomes by karyotyping takes around two weeks, 
irrespective of the method used. By using a FISH test (fluorescent in situ 
hybridisation) diagnosis of selected chromosomal aneuploidies, e.g. trisomy 13, 18 
and 21, X, and Y may be performed within 2-3 days (Eiben et al. 1998; Isaksen et al. 
2000). 
 
Trisomy 21 is the most common chromosomal aberration in infants, with a prevalence 
of about 1.6 in 1000 newborns in Norway (Medisinsk fødselsregister 2003/2004). 
Due to its known association with all trisomies, maternal age was the first criterion for 
screening for trisomy 21 (Hook 1981; Ferguson-Smith and Yates 1984; Adams et al. 
1987). Karyotyping of fetuses of mothers beyond 35 years of age is claimed to 
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prenatally identify about 30% of all fetuses with trisomy 21, assuming that 5-8% of 
all pregnant women are within this age group (Nyberg et al. 1990; Snijders et al. 
1998). Obviously, the detection rate is a function of the maternal age distribution in 
the population. The maternal age is increasing in Norway as elsewhere in the western 
world. At present the mean maternal age at delivery in Norway is 30 years 
(Statistisk sentralbyrå 2007). 
 
In the 1980s, another screening method for trisomy 21 was established including 
measurement of various maternal serum proteins of fetoplacental origin. These second 
trimester multiple-markers mostly comprise alpha-fetoprotein (AFP), human 
chorionic gonadotropin (hCG), unconjugated estriol (E3) and Inhibin-A, and are 
offered as a routine to pregnant women in the UK, USA, Europe and Australia etc. 
since the 1990s (Canick et al. 1988; Palomaki et al. 1997). With a 5% false-positive 
rate, these tests yield sensitivities of 67-76% for trisomy 21, depending on whether 
menstrual or sonographic dating is used (Wald et al. 1997).  
 
In the 1990s, a correlation between nuchal fluid accumulation and trisomy 21 was 
found at first trimester ultrasound (Szabo and Gellen 1990).This led to an introduction 
of a first trimester scan combining maternal age with measurements of the fetal nuchal 
translucency (NT) thickness at 11-13+6 weeks of gestation. Studies reported that 
approximately 75% of trisomy 21 fetuses had increased nuchal translucency (NT) 
thickness (Nicolaides et al. 1992; Pandya et al. 1995). Subsequently, maternal age was 
combined with fetal NT and maternal serum biochemistry (free β-hCG and PAPP-A, 
the double test) yielding detection rates as high as 87% - 92% for trisomy 21 with a 
false positive rate of 5% (Spencer et al. 2000; Cuckle 2002; Nicolaides 2004; 
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Nicolaides et al. 2005). Studies have reported detection rates up to 97% for trisomy 21 
when adding the absence of nasal bone to NT measurements, serum biochemistry and 
maternal age (Cicero et al. 2003). 
 
Invasive prenatal diagnosis for trisomy 21 with amniocentesis or chorionic villus 
sampling is offered to women with advanced maternal age in most western countries 
at 35 years of age, and in Norway at 38 years. Additionally, invasive testing is offered 
to women who have fetal abnormalities at the second trimester ultrasound 
examination. 
 
Second trimester ultrasound examination alone has never and will probably never 
become a preferred procedure to detect trisomy 21, because it largely relies on 
detection of typical associated anomalies. Such anomalies in trisomy 21 fetuses may 
be found in only 33% of fetuses (Nyberg et al. 1990). At 18 weeks, trisomy 21 fetuses 
may have brachycephaly, mild ventriculomegaly, flattening of the face, nuchal edema, 
atrioventricular septal defects, duodenal atresia and echogenic bowel, mild 
hydronephrosis, shortening of the limbs, “sandal gap” between first and second toe 
and clinodactyly or mid-phalanx hypoplasia of the fifth finger (Nicolaides 1992). 
Detection rates vary, as in unselected populations between 6.3% in a Scandinavian 
multicenterstudy (Jørgensen et al. 1999), and 26% in a European multicenter study 
(De Vigan et al. 2001). An overall detection rate of 46% was achieved in a French 
register study, when only the cases with anomalies detected by ultrasound were 
counted (Cans et al. 1998). In this study, the detection rate increased in the last period 
of investigation due to the introduction of an additional first trimester scan.  
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The detection rate of trisomy 21 was 68% based on maternal age and mid-trimester 
ultrasound scan in a maternity unit in Southampton, UK, between 1993 and 1998. 
However, the detection rate was only 41% in younger women (<35 years), when cases 
detected as a result of privately arranged serum or nuchal translucency screening were 
excluded (Howe et al. 2000). It is difficult to find recently published studies on 
detection rates of trisomy 21 based purely upon the second trimester scan. This is a 
consequence of the fact that first trimester scans in addition to biochemical tests, are 
offered in most countries. This obviously has a strong influence on the published 
results and the interpretation thereof. 
 
In selected populations, trisomy 21 could be identified with ultrasound in the second 
trimester with a sensitivity of 43%-90% (Benacerraf et al. 1987; Rotmensch et al. 
1997; DeVore 2000). These results are most likely due to a selection bias, as 
indications for referrals often were advanced maternal age, abnormal biochemical 
screening, previous children with trisomy 21, pathological routine scans etc., and the 
figures cannot be compared to results from non-selected populations. 
 
In conclusion: The increased detection rate of trisomy 21 in most countries, is due to a 
shift away from the second trimester scan including second trimester biochemical 
tests, toward a first trimester scan including the double test, which has improved the 
detection rates significantly (Cicero et al. 2003). 
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Facial clefts 
 
Cleft lips with or without cleft palate rank among the most frequent birth defects 
(Kraus et al. 1963; Benacerraf and Mulliken 1993), occurring in approximately 1 per 
1000 live births. There is a variation between racial and ethnic groups. The prevalence 
is higher in Orientals and lower among Africans (Ferguson 1988; Bianchi et al. 2000). 
Approximately 350 syndromes have been linked with facial clefting, some of which 
are lethal or include severe morbidity (Gorlin et al. 1971). Multiple nutritional and 
toxicological factors have been identified as causal agents (Wyszynski and Wu 2002; 
Murray and Schutte 2004; Hrubec et al. 2006). 
 
The palate is formed during the intrauterine LMP-based weeks 8-12; the primary 
palate is a very small anterior part of the palate, comprising the anlage of the 
premaxilla. This part of the bone must fuse with the posterior part, called the 
secondary palate. This is the major portion of the palate formed by fusion of two 
maxillary outgrowths named palatine shelves. The anatomical junction between the 
anterior and posterior shelves is called the incisive foramen (Figure 1). The incisive 
foramen is considered the dividing landmark between the anterior and posterior cleft 
deformities. Those anterior to the incisive foramen include cleft lip and cleft upper 
jaw. Such defects are due to a partial or lack of fusion of the maxillary prominence 
with the medial nasal prominence on one or both sides. Those defects that lie posterior 
to the incisive foramen include cleft palate and cleft uvula, and result from a lack of 
fusion of the palatine shelves. 
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Figure 1. 
Ventral view of the normal palate, gum, lip and nose. Reprint from Langman’s Medical Embryology, 
10th Edition 2006, T.W.Sadler, Head and Neck, Firgure 16.28, Page 276, with permission of Lippincott 
Williams & Wilkins. 
 
 
The initial detection of cleft lip and palate may result in the finding of associated 
further malformations in 36%-63% of the cases (Shprintzen et al. 1985; Stoll et al. 
2000). Thus, most authorities emphasize that the prenatal detection of anomalies 
should always generate a more extensive examination including karyotyping and a 
search for additional anomalies to obtain a precise diagnosis and prognosis (Levi 
2002). Several studies have shown considerable variation in the detection rates of 
facial clefts, ranging from 0 to 91% (Levi et al. 1991; Bronshtein et al. 1994), which 
implies that the ultrasound diagnosis of facial clefts still remains a challenge. 
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The clefts can be found as either isolated clefts of the anterior or posterior part, or a 
combination thereof, as shown in Figure 2. 
 
 
Figure 2. 
Common varieties of cleft lip and palate. A, Unilateral cleft passing through the lip and between the 
premaxilla (primary palate) and secondary palate. B, Bilateral cleft lip and palate. C, Midline palatine 
cleft. D, Bilateral cleft lip and palate continuous with a midline cleft of the secondary palate. Reprint 
from: Human Embryology and Developmental Biology, B.M. Carlson, Third Edition, 2004, Head and 
Neck, Figure 14-18, Page 337, Mosby Inc (Carlson 2004) with permission from Elsevier. 
 
 
The parents should be explained that children with facial clefts ought to be treated by 
a multidisciplinary specialist “cleft team” that may include surgeons, ear-nose-and-
throat specialists, orthodontists, speech therapists, audiologists and dentists. The 
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timing for surgery varies, but usually an operation to close a cleft lip will be done 
when the child is three months old. Surgery for cleft palates is usually performed 
around 12 months. Further surgery may be needed later in childhood to improve the 
appearance of the lip and nose and the function of the palate. 
 
 
Talipes equinovarus 
 
Clubfoot, or congenital talipes equinovarus (TEV), is one of the most common 
congenital birth defects (Drvaric et al. 1989; Lochmiller et al. 1998). The prevalence 
of isolated TEV is 1 per 1000 live births (Wynne-Davies 1972; Cowell and Wein 
1980). TEV is characterized by a deformity of the fetal foot fixed in adduction, 
supination, and varus position. There is subluxation of the talo-calcaneo-navicular 
joint, with underdevelopment of the soft tissues on the medial side of the foot and 
frequently of the calf and peroneal muscles (Drvaric et al. 1989), (Figure 2). 
 
 
Figure 2. 
TEV, with X-ray 
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As a result, the foot is typically turned inwards giving the foot a club-like appearance. 
At prenatal ultrasound the diagnosis of TEV is made when the foot is orientated in the 
same plane as the lower leg, and visualization of the tibia and fibula are possible in 
the same section as the foot (Figure 3). 
 
Clubfoot was first depicted in ancient Egyptian tomb paintings, and treatment was 
described in India as early as 1000 B.C. The first written description of clubfoot was 
given by Hippocrates (circa 400 B.C.), who believed the causative factor to be 
mechanical pressure due to deforming forces in the uterus. Today a number of 
hypotheses still remain, and research findings do not clearly support any particular 
one. Proposed mechanisms are uterine restriction, abnormalities of joint and/or bone 
formation, connective tissue, distal limb vasculature, neurological development, 
muscle migration or an underlying developmental abnormality or developmental 
arrest (Miedzybrodzka 2003). There is strong evidence that a genetic component may 
be the etiology of talipes equinovarus (Idelberger 1939). In Idelberger’s twin study, 
monozygotic twin concordance (32.5%) was much greater than dizygotic twin 
concordance (2.9%). Most authors seem to regard both environmental and genetic 
factors as playing a role. Toxins, temperature and seasonal-infective pathogens have 
been postulated as possible etiological factors as well (Pryor et al. 1991). There have 
been studies supporting seasonal changes (Pryor et al. 1991; Barker and Macnicol 
2002) and studies concluding with its non-existence (Loder et al. 2006). A high 
incidence of TEV is associated with early amniocentesis (11-12 gestational weeks) 
versus amniocentesis in the second trimester (15-16 weeks) (Tredwell et al. 2001). 
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When diagnosed in the neonatal period, approximately one third of the cases of TEV 
are reported to be isolated (Wynne-Davies 1972). TEV is frequently associated with 
other fetal anomalies, including aneuploidy; thus, a thorough examination of the 
whole fetus is important whenever the diagnosis of TEV is suspected in the prenatal 
ultrasound examination (Yamamoto 1979; Benacerraf 1986; Mammen and Benson 
2004). It is reported that after detection of a clubfoot, further scrutiny can result in 
detection of additional defects in 80% of cases (Rijhsinghani et al. 1998). 
 
 
 
Figure 3.  
Prenatal ultrasound demonstrating the visualization of the fetal foot and tibia and fibula in the same 
plane 
 
There are two methods of treatment for talipes equinovarus: medical and surgical. 
The aim of the medical therapy is to correct the deformity early and fully and to 
maintain the correction through manipulation, casting, and splintage alone. The most 
frequently used surgical approach is the posteromedial release, which has many 
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variations. However, long-term follow-up studies have shown that the results of 
surgical treatment are disappointing. Increasing foot pain, weakness, and stiffness 
often lead to premature arthritis and disability of the foot (Hutchins et al. 1985; 
Aronson and Puskarich 1990; Kite 2003). 
Ponseti, at the University of Iowa, developed an alternative non-operative method in 
the 1950s. This method comprises weekly repetitive manipulations of the clubfoot 
with plaster casting where the components of the clubfoot are treated in sequence. For 
approximately 40 years, Iowa City was the only place where the Ponseti Method was 
practiced. He reported satisfactory functional results in 89% of the individual cases he 
treated (Laaveg and Ponseti 1980). After 30 years of follow-up, he concluded that 
excellent or good functional outcomes were achieved. Ponseti published a book on his 
method in 1996 (Ponseti 1996) and the Internet has been instrumental in getting the 
word out worldwide to parents and surgeons (Morcuende et al. 2003). The Ponseti 
Method is now the universal method of choice (Colburn and Williams 2003; Heilig et 
al. 2003; Morcuende et al. 2004; Faulks and Luther 2005). 
 
 
European registry studies 
 
Detection of a congenital anomaly by ultrasound is a rare event. Thus, large numbers 
of fetuses need to be examined in order to find enough cases to draw scientifically 
sound conclusions on prevalence and typical ultrasound appearance. In Europe there 
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are two major registries, the EUROCAT and the Euroscan study, which contain some 
of the largest published ultrasound materials on congenital malformations. 
 
In 1979 the EUROCAT registry was started with the aim of recording congenital 
anomalies. This European registry records congenital anomalies in 30 geographical 
areas from 15 countries, mostly from within the European Union. The purpose is 
epidemiological surveillance of birth defects. Data from approximately 300 000 births 
and 5 000 congenital anomalies per year have been gathered (EUROCAT 1997). 
 
The aims of the Euroscan study were to evaluate the feasibility of routine ultrasound 
scanning across Europe, and to evaluate the prenatal detection rate of all congenital 
malformations and termination of pregnancies in unselected populations. Data were 
provided from 16 registries collaborating with the EUROCAT registry and four 
registries without EUROCAT collaboration, from a total of 12 European countries. 
The study period was from 1996 to 1998. Altogether, 8 126 malformed 
fetuses/newborns were diagnosed in a total of 709 030 consecutive births in the areas 
covered by the registry (Clementi and Stoll 2001). Facial clefts (Clementi et al. 2000) 
and chromosomal anomalies (De Vigan et al. 2001) are among the anomalies that 
have been studied within the large population. 
 
In a region around the city of Strasbourg, northern France, all fetuses, terminations 
and newborns were included in the registry covering 11 maternity hospitals for the 
period 1979-1999. The registries included approximately 280 000 consecutive births. 
From this material, several important reports have been published, for example 
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addressing oral clefts (Stoll et al. 1991) and fetal chromosome abnormalities (Stoll et 
al. 1993). 
 
Additionally, a multicenter study called Multicentric Eurofetus Study was designed to 
evaluate the sensitivity of ultrasound routine screening for fetal malformations. The 
screening was applied to 200 000 pregnant women examined by ultrasound in 60 
obstetrical ultrasound hospital laboratories in 14 European countries (Levi and 
Montenegro 1998; Grandjean et al. 1999). Alltogether, 3 685 malformed fetuses were 
recorded prospectively between 1990-1993. The main study results have been 
summarized by Grandjean et al. showing a 61.4 % sensitivity of the 3 685 minor and 
major malformed fetuses, and a 41% elective termination rate for severe 
malformations (Levi et al. 1991; Levi et al. 1995; Levi and Montenegro 1998; 
Grandjean et al. 1999). In addition, Levi contributed with several important studies 
(Levi et al. 1991; Levi et al. 1995; Levi and Montenegro 1998). 
 
Compared to these European data, our material highlighted some significant 
differences between our non-selected Norwegian population and other European 
countries, which are addressed in this thesis. 
 
 
Improved fetal imaging – improved detection of anomalies 
 
The technology of ultrasound has had an extensive development from its early 
introduction into medical use in the 1950s. Additionally, the practitioners have 
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developed better skills with introduction of formal education. Approved by the 
American Institute of Ultrasound in Medicine, the American Society of Ultrasound 
Technical Specialists was established in 1970, the first accreditation of educational 
programs occurred more than ten years later in 1982 (Baker 2005). Today, 
postgraduate ultrasound programs for sonographers are established in several 
countries, such as the USA, Canada, Australia and the United Kingdom. In 1997, the 
National Center for Fetal Medicine established a postgraduate educational program in 
obstetric ultrasound for nurse/midwives at the university level in Trondheim. So far, 
unfortunately, this is the only program of its kind in Scandinavia. The importance of 
operator education is obvious, and has been confirmed by a study showing that 
education and experience of the operator had a significant impact on the detection rate 
of congenital heart defects (Tegnander and Eik-Nes 2006). 
 
Many authors have described improved detection rate of anomalies over time (Carrera 
et al. 1995; Grandjean et al. 1999; Stoll et al. 2002; Richmond and Atkins 2005; 
Tegnander et al. 2006). A second important development resulting from improved 
fetal imaging is the increased use of ultrasound in the first trimester. Early sonography 
at 11- 14 weeks may detect major structural defects; reported detection rates vary 
between 41% - 65% (Hernadi and Torocsik 1997; D'Ottavio et al. 1998; Economides 
and Braithwaite 1998; Whitlow et al. 1999). 
 
Grandjean reported that in fetuses with malformations, the average number of 
malformations per fetus was 1.25, so a search for other anomalies should always be 
included (Grandjean et al. 1999). In an editorial, Clementi and Stoll stated that: “ in 
all countries all malformations have a significantly lower detection rate if isolated, 
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confirming that anomalies have a higher chance of being detected if associated with at 
least one other major malformation” (Clementi and Stoll 2001). This statement has 
been confirmed at our center as well (Tegnander et al. 2006; Offerdal et al. 2007). 
 
 
Consequences of prenatal diagnosis of fetal anomalies 
 
The potential advantages of prenatal diagnosis are fetal treatment, customized 
surveillance and improved outcome (Touloukian and Hobbins 1980; Romero et al. 
1988; Bonnet et al. 1999; Brantberg et al. 2002; Lindley et al. 2006). Intrauterine 
therapy, selective preterm delivery, choice of the mode of delivery, transportation of a 
sick fetus in utero and selective termination of pregnancy may all be consequences of 
prenatal diagnosis (Crombleholme et al. 1996). Intrauterine therapy, including fluid 
aspiration or permanent drainage, blood transfusions (Hansmann et al. 1989), 
shunting, laser coagulations (Hecher et al. 2000; Ong et al. 2006; Middeldorp et al. 
2007; Oepkes et al. 2007) and pharmaceutical therapy (Gembruch et al. 1989) are all 
factors that represent the increasing spectrum of fetal treatment. 
 
Fetal/neonatal lives can be saved by prenatal diagnosis and adequate fetal medicine. 
Several papers show improved conditions preoperatively for newborns with a heart 
defect when detected prenatally (Bonnet et al. 1999; Tworetzky et al. 2001; Franklin 
et al. 2002). Although surgical results are similar, the reduced morbidity decreases 
surgical delays and potentially may impact on neurodevelopmental outcomes and 
long-term outcome (Jacobs and Norwood 1994; Eapen et al. 1998; Kumar et al. 1999; 
Mahle et al. 2000). A study on prenatal detection of gastroschisis, indicated improved 
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outcome by close CTG surveillance in the third trimester, through detection of 
intrauterine stress and thereby reducing the risk of IUFD (Brantberg et al. 2004).  
 
 
Counseling 
 
Improved knowledge of the occurrence of different anomalies as they appear in a non-
selected population, and knowledge of the frequency of isolated and associated 
anomalies is necessary for providing correct counseling. In our department, we have a 
multidisciplinary perinatal team, who participate in the counseling process when 
anomalies are detected. Depending on the diagnosis, pediatric surgeons, 
neurosurgeons, plastic surgeons, pediatricians, pediatric cardiologists, obstetricians, 
specialists in fetal medicine as well as midwives and social workers are included in 
the counseling team. In some cases other parents of a child with a particular disorder 
have taken part in the counseling process. Most parents are unfamiliar with the 
diagnosis, so it is important to explain about the nature of the anomaly, the prognosis 
as well as the management options. In this setting it is challenging to give a balanced 
presentation of the prognosis. Over the years as we have realized the difficulty and 
importance of counseling and our counseling process has continuously been 
developed. In 1997, two social workers were added to the team, one of their 
contributions is to provide detailed information about the postnatal support program 
offered by the health authorities for the various developmental disorders. We have 
empirical reason to believe that the discussion concerning whether or not to terminate 
a pregnancy with a fetus with a future disability is partly influenced by the support our 
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society offers. Counseling parents is a difficult task involving the fine-tuned balance 
between being objective and directive. 
 
Fetal medicine is a relatively new field. For many conditions, the prognosis of the 
developmental disorder is dominated by the experience from cases that survived 
pregnancy, birth and the immediate neonatal period: the neonatal population. 
However, it is incorrect to inform about the prognosis based mainly on the neonatal 
population as long as the time of diagnosis usually takes place between 12 and 20 
weeks in pregnancy. Counseling has to be based on long-term follow up of large 
prenatally diagnosed populations. An example is counseling about the diagnosis of 
omphalocele. In a study by Brantberg with 90 fetuses with omphalocele, only 21 
(23%) survived and only 8 (9%) infants were alive and healthy (Brantberg et al. 
2005). This is due to a strong association between omphalocele and other associated 
anomalies including an abnormal karyotype. It reflects a strong contrast to a neonatal 
population of omphalocele with survival rates in the range of 90% (Mayer et al. 1980; 
Rankin et al. 1999). Similar results were found in a study of prenatally detected 
congenital heart defects (Tegnander et al. 2006). This emphasizes how important it is 
to base the counseling process on large follow up data from the time of diagnosis, 
through pregnancy, birth, the neonatal period and possibly further on. 
 
All counseling and all treatment decisions following detection of anomalies should 
also be based on international nomenclature and standards.  
The term congenital anomaly usually refers to structural defects (congenital 
anomalies, disruptions and dysplasia), chromosome aberrations, inborn errors of 
metabolism and hereditary diseases. In contrast, a malformation may be defined as: 
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“Any anomaly detected at birth or apparent within the first postnatal years, which is 
likely to result in death, disfigurement or disability, and which is likely to require 
medical or surgical treatment” (National Perinatal Epidemiology Unit 1995). 
 
The World Health Organization defines disability as: ”Any restriction or lack 
(resulting from an impairment) of ability to perform an activity in the manner or 
within the range considered normal for a human being” (International Classification 
of Impairments, Disabilities and Handicaps. Geneva. WHO 1980). It is of importance 
to define the grade of disability when counseling, and discussing the clinical domains 
in which it can appear. Disability can be measured according to: malformation and 
congenital abnormality, neuromotor function, auditory function, communication, 
visual function, cognitive function or other physical disabilities. In clinical domains 
there are grades of severity from severe to moderate to mild disabilities. There are 
different classification systems to group disabilities and anomalies 
(National Perinatal Epidemiology Unit 1995; Marlow et al. 2005). Severe disability is 
defined as an ability that makes the child highly dependent on caregivers and IQ score 
more than 3 SD below the mean, profound sensorineural hearing loss, or blindness 
(National Perinatal Epidemiology Unit 1995; Marlow et al. 2005).  
We extended the prognostic categories suggested by others 
(Report of the RCOG Working Party 1997; Bricker et al. 2000) and added examples 
(Table 1).
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Most studies report that the prenatal detection of congenital anomalies is seen as 
advantageous by the parents (Detraux et al. 1998). It is widely accepted that prenatal 
detection is of benefit for the postnatal course of parental distress, because parents 
will be prepared before the hospitalization period of their future child (Detraux et al. 
1998). Detraux et al. concluded: “Antenatal diagnosis made with more and more 
sophisticated techniques and competencies, is desirable. It allows not only for better 
psychological preparation in making a decision regarding termination of pregnancy, 
but also in taking care of the future impaired child. It should be stressed however, that 
any detection is ethically correct only if consequences are correctly assumed. Women 
are able to cope with a birth defect, but need professionals who are responsive to their 
psychological difficulties” (Detraux et al. 1998). It is known that prenatal consultation 
by pediatric surgeons may have a significant impact on the perinatal management of 
the fetus with a surgically correctable congenital anomaly (Crombleholme et al. 
1996). Changes in management including termination of pregnancy, in utero 
intervention, mode or timing of delivery have been described (Crombleholme et al. 
1996). To our knowledge few authors contradict the positive effect of parents’ 
experience by prenatal diagnostic and counseling (Hunfeld et al. 1999).  
 
Counseling is not only of high importance when the anomalies are severe, but also 
when the anomalies are correctable after birth, leaving only slight cosmetic 
impairment. Prenatal counseling when facial clefts were diagnosed prenatally, showed 
that prenatal contact with a cleft team was experienced as valuable (Matthews et al. 
1998). Sagi postulated in a study with 77 parents of children with clefts that the 
knowledge gained reduced uncertainty and gave the parents an increased sense of 
personal control (Sagi et al. 1992). In a 2004 study from Switzerland, with 29 couples 
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interviewed, 93% of the parents felt well prepared psychologically for the birth of 
their child and 96% considered prenatal diagnosis a benefit (Rey-Bellet and Hohlfeld 
2004). 
 
Clubfoot is a minor structural anomaly. But parents who had no antenatal diagnosis, 
almost all referred to the initial shock at birth and the lack of immediate information 
and reassurance that the condition was correctable (Burgan et al. 1999). The same 
authors concluded “that parents required adequate antenatal counseling to improve the 
understanding of the history and treatment of this condition”. The ability to counsel 
patients appropriately necessitates accurate diagnosis of both the foot deformities 
itself and of the associated anomalies (Treadwell et al. 1999). 
 
In contrast, Skari concluded that prenatal diagnosis of congenital malformations was 
associated with increased parental psychological distress after birth compared to 
distress in parents of babies with postnatal diagnosis (Skari et al. 2006). The 
suggested explanation from Skari et al. was that the duration of the latency from 
prenatal diagnosis to definitive surgical treatment was inversely related to parental 
distress. The lowest distress levels were seen in parents who were told about 
pathology after birth, and this group was characterized by short latency from 
diagnosis to surgical treatment. The authors however, did not discuss that a prenatally 
undiagnosed anomaly sometimes might be of a minor character and therefore the 
psychological distress might not be correlated to the same extent of burden or grief. 
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Termination of pregnancy 
 
Termination of pregnancy (TOP) after prenatal diagnosis of major congenital 
anomalies is allowed in the second trimester (< 22nd-24th gestational week) in most 
countries. In France, Spain, UK and Germany, TOP is possible at any time of the 
gestation provided there is a severe fetal condition. There are large variations between 
countries regarding the rate of TOP. The lowest rates of TOP were observed in 
countries without an offer of a routine fetal examination and the Eastern European 
countries, while the highest were found in countries with three routine scans as 
Germany, France, Italy, Spain, Croatia and in the UK (Clementi and Stoll 2001). 
 
According to Norwegian law (LOV 1975-06-13 nr 50 1975), the woman has a right to 
make the final decision about a termination of pregnancy before completed 12 weeks 
gestation. After 12 completed weeks, the woman must apply for a termination, and 
grounds for this are enumerated in subparagraphs. Still major consideration should be 
given to the woman’s own assessment of her situation, but the conditions for 
authorization of termination of pregnancy becomes more stringent as the duration of 
the pregnancy increases. One of five criteria must be fulfilled to qualify for a 
termination of pregnancy after completed 12 weeks. 
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According to Norwegian Law (LOV 1975-06-13 nr 50 1975) these are: 
 
1. The pregnancy, childbirth, or care of the child may cause unreasonable strain 
 upon the physical or mental health of the woman. 
2. The pregnancy, childbirth, or care of the child may place the woman in a 
 difficult position. 
3. There is a major risk that the child may suffer from a serious disease as a 
 result of its genotype or a disease or harmful influences during pregnancy. 
4. The woman became pregnant as a consequence of incestuous sexual relations 
 or rape. 
5. The woman is suffering from severe mental illness or is mentally retarded to a 
 considerable degree. 
 
A pregnancy may not be terminated after 18 completed weeks of gestation, unless 
there are particular important grounds for doing so, as for example severe fetal 
malformations. If there is a reason to believe that the fetus is viable, authorization for 
a pregnancy termination shall not be granted. According to practice this has led to a 
limit of completed 22 weeks of gestation. Later in gestation termination of pregnancy 
is only permitted if the diagnosed anomaly is lethal. 
 
When parents are confronted with a fetal diagnosis, a number of questions arise and 
many decisions have to be made. The necessity to make a decision is by itself a 
source of stress. Parents may have to decide whether or not to karyotype or to attempt 
intrauterine therapy, whether or not to change mode of delivery or deliver early, or 
deliver in a tertiary center. The decision to terminate or not is often dependent upon 
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the diagnostic information of the ultrasound results and subsequent test results (Levi 
2002). The prenatal detection of serious and lethal anomalies has been shown to 
increase the termination rate and causes a reduction in neonatal mortality rates (Stoll 
et al. 2002). Termination rates can differ, depending on organ system involved, and 
structural anomalies are terminated at other rates than chromosomal. A study from a 
well-defined population in northeastern France showed increased termination rates 
following increased prenatal detection rates in the time period 1979-1999 (Stoll et al. 
2002), with higher TOP rates for chromosomal anomalies than for non-chromosomal 
anomalies. The same was seen in a population based study of over 500 000 infants 
born over a 16-year period in Northern England, where it was concluded that 
diagnostic accuracy improved over time. At the same time termination of pregnancy 
for fetal malformation more than doubled (Richmond and Atkins 2005). A study of 
Mansfield (Mansfield et al. 1999) showed that TOP following prenatal diagnosis of 
trisomy 21 and anencephaly were estimated to be 92% and 82%, respectively, based 
on a systematic review, including studies from different countries in the USA, UK 
and Europe. The termination rates occurred in 41% of severe malformations 
(Grandjean et al. 1999) in the Eurofetus study from 61 European obstetric units. 
However, in the Eurofetus study, a large difference in the ratio of termination was 
detected, independently of the ultrasound scan policy as well. This attitude was 
considered dependent on religious, ethical, cultural and private reasons, as well as the 
medical counseling received (Clementi and Stoll 2001).  
 
Several researchers have tried to find the determinants of parental decisions to 
terminate a pregnancy. Studies mainly agree that the severity of anomalies directly 
correlates with the termination rate (Drugan et al. 1990; Evans et al. 1996; 
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Schechtman et al. 2002; Mezei et al. 2004; Shaffer et al. 2006). In addition, Shaffer 
found that the type of diagnostic procedure, maternal age and ethnicity contributed to 
patient’s decision making in the setting of fetal aneuploidy (Shaffer et al. 2006). The 
author discussed that women who select CVS rather than amniocentesis are likely a 
different group of patients, and may have a lower tolerance for fetal abnormality and 
are more likely to have made their decision to terminate for any abnormality. Older 
maternal age at diagnosis has also been associated with a higher rate of decision to 
terminate an affected pregnancy (Drugan et al. 1990; Schechtman et al. 2002; 
Forrester and Merz 2003; Shaffer et al. 2006), although some studies have found an 
association with the decision to continue the affected pregnancy (Holmes-Siedle et al. 
1987). Hispanic women were less likely to terminate an affected pregnancy 
(Cunningham and Tompkinison 1999) than Filipino women (Shaffer et al. 2006), 
which shows that cultural and religious factors are likely contributing factors to the 
complex and challenging decision of whether or not to terminate an affected 
pregnancy. 
 
Interestingly, in some studies the diagnosis of an anomaly in the first trimester was 
not more likely to lead to a termination of pregnancy than in the second trimester 
(Drugan et al. 1990; Evans et al. 1996) whereas the gestational age was a significant 
factor in another study (Kramer et al. 1998). 
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The influence of termination of pregnancy on perinatal mortality 
 
During the 1960s and 1970s, the overall infant mortality rates in industrialized 
countries declined substantially because of improved perinatal care, including the 
advent of neonatal intensive care and the increased use of cesarean delivery (Williams 
and Chen 1982). However, the rates of infant deaths due to congenital anomalies 
remained unchanged, and consequently the proportion of infant deaths attributable to 
congenital anomalies rose during this period (Goldenberg et al. 1983). A report on 
congenital anomaly-related infant mortality rates in Canada, England, Wales and the 
US was published by Liu (Liu et al. 2002). It showed that fetal deaths caused by 
congenital anomalies at very early gestation (20-25 weeks) had increased dramatically 
in recent years, while fetal and infant deaths at later gestation had declined. Prenatal 
diagnosis and selective termination of pregnancies affected by congenital anomalies 
were concluded to be the major factors responsible for the accelerated decline in 
infant deaths. It was suggested that further declines in infant mortality in 
industrialized countries could be expected as a result of increased use of prenatal 
diagnosis. Such consequences of prenatal diagnosis of congenital anomalies followed 
by termination of pregnancy on the perinatal mortality have also been described by 
others (Wen et al. 2000; van der Pal-de Bruin K.M. 2002). 
40 
 
Prenatal screening program 
 
The first nationwide official prenatal screening program in Norway was introduced in 
December 1983. At that time Torbjørn Mork, head of the Norwegian Directory of 
Health, issued a letter with a short list of the indications for prenatal screening: (IK-
1077, 1983). 
1. Parents who already have a child with chromosome aberrations. 
2. Parents who already have a child with a neural tube defect. 
3. Parents who already have a child with hereditary metabolic disease, where 
genetic diagnosis is possible. 
4. Parents who already have a child with severe X-linked recessive disease, or 
when there is a high risk that the mother is a carrier. 
5. In cases were one of the parents is a carrier of a chromosome aberration and 
therefore has a high risk for a child with a severe developmental disease. 
6. Parents with a high risk of having a child with a chromosome aberration due to 
the woman’s age. Prenatal diagnosis is offered women over 38 years. 
 
Initially, women at risk were offered an amniocentesis for analysis of the karyotype 
and amnion alphafetoprotein, the latter to detect neural tube defects. Later, chorionic 
villus sampling and chordocentesis were added. Since 2004, selected women at risk 
have been offered a first trimester NT ultrasound examination. Screening for trisomy 
21 using serum biochemistry tests were officially forbidden by the health authorities 
until 2006. First in late 2006 a serum marker-screening program (double test) was 
introduced in combination with a first trimester NT ultrasound examination, but only 
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to the specific group of pregnant women at risk. In addition, prenatal diagnostic has 
been offered when fetal anomalies were diagnosed at the ultrasound examination. 
 
Following a consensus conference one ultrasound examination at 18 weeks of 
pregnancy was introduced in 1986 in Norway for all pregnant women (Backe and 
Buhaug 1986). Within a few years a survey concluded that approximately 98% of the 
women accepted the offer (Backe 1994). 
 
In the late 80s and early 90s, the diagnosis of fetal anomalies was increasingly 
discussed in Norway. In 1995 a second consensus conference was held. The offer of a 
routine fetal examination to all pregnant women was continued, but informed consent 
by the pregnant women was requested (Konsensuskonferansen 1995). Additional 
ultrasound examinations were available based on clinical indications such as bleeding, 
pain, uterus larger or smaller than expected, anxiety etc. 
 
A new Norwegian law was introduced in 2003 (LOV-2003-12-05-100. 2003) in part 
with the intention to limit the use of early ultrasound. Early prenatal ultrasound 
(11+0-13+6 week scan) was thereafter centralized to 6 teaching hospitals. Women 
and pregnancies who did not fulfill the previous criteria could be admitted to early 
ultrasound examination in case of clinical indications and now also in case of anxiety. 
Instead of limiting the number of early ultrasounds, the public discussions of the topic 
led to an increased number of early ultrasound examinations. 
 
The rate of women who have accepted the offer of amniocentesis due to maternal age 
throughout Norway is registered in a national register at the Directorate for Health 
42 
and Social Affairs. It is the responsibility of the first line medical health care to 
inform patients about this offer. However, from experience it is well known that some 
patients do not get this information. 
 
 
Ethics 
 
Whether it concerns prenatal diagnosis, giving treatment or rejecting treatment 
prenatally or terminating a pregnancy, fetal medicine has been, and still is in the 
crossfire of ethical discussions. This ethical debate has been particularly intense in 
Norway (Solberg 2003) in comparison with other Scandinavian countries. Norway 
has until now always had a political culture of protecting the individual strongly, also 
the fetus after 12 weeks. There is a strong focus on integration of disabled people. The 
association for disabled people, Norges Handikapforbund, has been active in political 
discussions when new proposals and regulations have been discussed. Also well-
known people in Norway have fronted their life with disabled children and showed 
that it can be a positive challenge. Many parents even claim to experience a new 
perspective of values in their lives as a consequence of having disabled children. 
Some have been rather critical towards the possibilities of termination of pregnancy. 
It seems important to have a strong political and public focus on the topic of 
termination of pregnancy, as well as on the detection of chromosome and/structural 
anomalies and the rights of disabled people. It leads to a broad acceptance of disabled 
people participating in the communities. 
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The topic of termination of pregnancy is a sensitive issue. It may be related to 
personal opinion, religion, public opinion or the national political guidelines, as well 
as common public perception. The decision of a termination of pregnancy is one of 
the most difficult ethical dilemmas parents can be confronted with (Zeanah et al. 
1993). Women who terminate pregnancies for fetal anomalies, grieve as intensely as 
those who experience a spontaneous perintal loss (Zeanah et al. 1993). The long-term 
psychological stress response associated with termination of pregnancy for fetal 
anomalies does not differ from the stress response seen in women who experience a 
perinatal loss (Salvesen et al. 1997). 
 
In the counseling process it is of vital importance for the prenatal team that the 
counseling is based on a correct diagnosis. False positive diagnosis leading to 
termination of pregnancy is not acceptable. Our perinatal pathologist, Isaksen found 
good correlation between prenatal diagnoses and postmortem findings, with the main 
diagnosis correct in over 90% (Isaksen et al. 1998; Isaksen et al. 1999; Isaksen et al. 
2000). This corresponds well with other studies, where similar results were found 
(Chescheir and Reitnauer 1994; Julian-Reynier et al. 1994; Stiller et al. 2001; Wald et 
al. 2004; Kaasen et al. 2006). In all the diagnostic results in this thesis, there was no 
major false positive diagnosis and in no cases a false positive diagnosis led to 
termination of pregnancy.
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AIMS OF THE STUDIES 
 
The second trimester routine ultrasound examination determines the gestational age, 
locates the placenta and detects multiple pregnancies. Another main purpose of the 
examination is to detect fetal structural anomalies. The detection of fetal disease 
including anomalies is the basis for fetal medicine. As part of a continuous quality 
assessment of prenatal ultrasound it is important to evaluate various consequences of 
a routine ultrasound examination program. The overall aim of this study is to 
contribute to this quality assessment in detection of both severe and less severe 
anomalies, as in studying the prenatal detection of trisomy 21 and studying the overall 
rate of termination of pregnancy, as well as the detection of talipes equinovarus 
(TEV) and facial clefts. It was of interest to also study specific anomalies that may be 
harmless and have good prognosis when occurring in isolation. Because the same 
anomalies could also be associated with very severe anomalies, some of which are 
difficult to diagnose anatomically; they then may have a completely different and very 
severe prognosis. 
 
 
The primary aims of the studies were: 
 
1. To evaluate prenatal ultrasound examination regarding the detection of talipes 
equinovarus (TEV) in a large non-selected population. Moreover, to study 
trends in detection rates over time, as well as the prevalence and outcome of 
isolated TEV and TEV with associated anomalies.  
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2. To evaluate prenatal detection of facial clefts by ultrasound in a large non-
selected population, and to study trends in detection rates over 18 years. We 
also studied the prevalence and outcome of the isolated cases as well as cases 
with associated anomalies.  
 
3. To evaluate the contribution of second trimester routine ultrasound 
examination as well as karyotyping due to maternal age, in the prenatal 
detection of trisomy 21 in a large non-selected population, in a time period 
when maternal biochemical screening and first trimester nuchal translucency 
screening were not used.  
 
4. To evaluate the influence of fetal ultrasound examination on termination of 
pregnancies in a large non-selected population and to look for changes in the 
rate of terminated pregnancies and the severity of the terminated anomalies 
over time. 
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MATERIAL AND METHODS 
 
Populations and study design 
 
The study population represented a non-selected population residing in a 
geographically well-defined area consisting of the city of Trondheim and eight 
surrounding municipalities as shown in Figure 4. Communities included in the study: 
 
1. Klæbu 
2. Malvik 
3. Melhus 
4. Midtre Gauldal 
5. Rissa 
6. Selbu 
7. Trondheim 
8. Tydal 
9. Åfjord 
 
 
Within this geographical area, 97% of the pregnant women residents had a routine 
fetal examination at the National Center for Fetal Medicine (NCFM) at St. Olavs 
University Hospital in Trondheim, and later delivered at that hospital. The University 
Hospital also includes the only neonatal intensive care unit and pediatric 
surgery/orthopaedic department for the follow up of the same population. In Norway 
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facial cleft surgery is centralized to two other university hospitals, University Hospital 
of Bergen and The National Hospital, University of Oslo. 
 
Specially trained sonographer midwives performed the routine fetal ultrasound 
examination between 16+1 and 22+5 gestational weeks. At the ultrasound 
examination, the biparietal diameter, the mean abdominal diameter and the femur 
length were measured. The number of fetuses, the fetal anatomy including the 
extremities, and the location of the placenta were assessed. All pathology found at the 
second trimester ultrasound examination was presented to specialists in fetal medicine 
at the center; these specialists also performed all ultrasound examinations for clinical 
indications, before and after the second trimester routine ultrasound examination 
including all necessary invasive procedures. 
 
The NCFM has a patient administrative system (PAS) in the form of an extensive 
database in which data have been prospectively registered for each pregnancy from 
the first ultrasound examination through the pregnancy, birth and the neonatal period, 
and thereafter. For each fetus with congenital anomalies, SVHS videos, DVD’s, 
biochemical results and karyotype were also registered. In addition, autopsy reports 
including photographs and x-rays were available for evaluation of the prenatal 
ultrasound findings in cases of TOP or IUFD. The registry used the nomenclature and 
coding system from the 9th and 10 th revision of the International Classification of 
Disease (ICD-9, ICD-10). The term congenital anomaly refers to structural defects 
(congenital malformations, disruptions and dysplasia), chromosome aberrations, 
inborn errors of metabolism and hereditary diseases. 
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A pediatrician examined clinically all newborns at the hospital within the first 24 
hours after birth. The immediate postnatal data are included in the database. For the 
whole study period, the main responsibility for the pediatric examination has been in 
hands of one senior pediatrician. Routines have been established to capture all 
congenital anomalies or syndromes diagnosed even years later to complete our 
database. All live-born infants were followed up; in this study the longest follow-up 
was over 18 years, the shortest about 2 years. The health care program in Norway 
ensures all children regular physical examinations at child health care centers until 
school age; there have been some minor changes through the studied periods, but this 
examination now is done at 6 weeks, 6 and 12 months, and at 2, 4 and 6 years of age. 
All relevant pathology led to referral to the pediatric department at our hospital, which 
communicated information about malformations, and syndromes to our unit. 
 
Cases of congenital anomalies referred to the NCFM as a tertiary referral center from 
outside our non-selected population were not included in the series presented in this 
thesis. 
 
All four articles are prospective follow-up studies. The first study covered the 15-year 
period from January 1987 through December 2001, during which 41 382 
fetuses/infants were registered as delivered from 16 weeks onwards. The second, third 
and fourth study covered the 18-year period from January 1987 through December 
2004, with a total population of 49 314 fetuses delivered after 16 weeks, all scheduled 
to be born at St. Olavs University Hospital. Of those, 49 314 (98%) had an ultrasound 
examination performed at the National Center for Fetal Medicine, and thus formed the 
study population. 
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Depending on the diagnosis, a perinatal team consisting of an obstetrician, a 
sonographer/midwife, a pediatrician, a pediatric surgeon and a social worker informed 
the parents at the time of diagnosis, and gave support until the delivery of the 
fetus/newborn. If a pregnancy was terminated, the doctor in charge, the “contact 
sonographer/midwife” and the social worker supported the parents during the process 
and during the time thereafter. 
 
 
Methodological considerations 
 
It is of importance to be aware of methods used to evaluate ultrasound studies. This is 
described by Levi (Levi 2002) in 9 comments: 
Assuming equivalent examiner skills, several factors act significantly on 
sensitivity.  
1. The choice of the population sample. Studies generally focus on a distinct 
geographical area, a specific hospital obstetrical clinic or on collaborative 
data. One type of study depicts the medical practice of a given area, in essence, 
a specific population screening. Another depicts an organizational approach to 
screening dependent upon a selected population and the motivation of the team 
to find malformations. A third encompasses the above features into a more 
standard practice.  
2. The selection of pregnant women. Studying pregnant women at ‘regular risk’ 
is equivalent to investigating results from a typical cross-sectional population. 
This represents a non-tertiary clinical setting. The terms ‘low risk’ and ‘regular 
risk’ used in many studies are probably meant to be equivalent. They are not. 
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Low-risk patients have a low fetal and maternal risk, but are often poorly 
quantified, while high-risk patients have seriously higher and better 
quantifiable risks. Screening pregnant women at high risk is likely to be much 
more effective since the odds of finding an anomaly are higher, examiner 
concentration is sharpened and personnel generally better trained.  
3. The gestational age at the ultrasound examination. Specific anomalies can be 
recognized at different gestational ages.  
4. The total number of ultrasound sessions. Theoretically, the more scans that 
are performed on a patient, the greater would be the rate of anomaly 
identification. For example, the RADIUS study results indicated that a third 
trimester scan added to the second trimester scan’s anomaly yield, but no one 
has yet addressed the efficacy of monthly scans.  
5. The distribution of malformations among systems. Malformations of the CNS 
are easier to detect than congenital heart defects (CHD). An abnormal 
distribution of these defects might change the results appreciably.  
6. The exclusion of fetal malformations. Studies that exclude certain anomalies 
because they are ‘minor’ or theoretically undetectable may have dramatically 
different results than when all anomalies are included in the analysis.  
7. The routine practice of autopsy for abortion, fetal and postnatal deaths. 
Autopsy and pathology examinations are considered as the gold standard for 
malformation assessment. However, autopsies are not routinely performed 
everywhere. Also, the quality of the autopsy can impact on false-positive and 
false-negative rates. Lastly, even pathological examination is not always 
infallible, especially for fragmented specimens.  
8. The accuracy of neonatal examination. This may also affect appreciably the 
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accuracy when only examinations of live-born infants are conducted.  
9. The period length of ascertainment. Usually, the period of observation is 
limited to a few days during the neonatal period. Series with longer observation 
periods are infrequent, yet some anomalies can wait several months or years to 
express themselves. “Nevertheless, a balance must be struck between 
pragmatism and obsession regarding study design”. 
 
These 9 comments summarize some of the main issues for a good study. There are 
major differences between fetal populations and neonatal populations regarding the 
incidence and development of anomalies. Especially regarding the severity and 
outcome of anomalies, there are major differences between the fetal and neonatal 
populations, as discussed in the section on counseling. Obviously, differences 
between fetal populations versus a postnatal population may apply to most anomalies. 
 
 
Prognostic categories 
In paper 4, a set of prognostic categories of anomalies detected with ultrasound was 
developed, ranging from 1 to 9, where number 1 represented the most severe and 9 
the best prognosis with a high survival rate (Table 1). Each of the terminated fetuses, 
the intrauterine and fetal deaths intrapartum or within 3 months postpartum was 
retrospectively categorized according to Table 1. 
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Statistical analysis 
 The observed frequencies were tested for significance using the chi square statistical test (SPSS 
11 for Mac OS X software package) in Paper 1-4, in Paper 1 groups were compared by the 
Fisher’s exact test. The level of significance was set at 5%.  
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RESULTS AND COMMENTS 
 
Paper 1 
Prenatal ultrasound detection of talipes equinovarus in a non-selected population of 49 314 
deliveries in Norway 
 
Results 
 
A total of 113 cases of TEV were registered during the 18-year period, 49% had isolated TEV 
and 51% had associated anomalies. During the 3 six-year periods, there was a significant 
improvement (P = 0.006) in the overall detection of TEV from 43% to 67% and 77%, 
respectively. The detection rate for isolated TEV increased significantly (P = 0.001) during the 
three time periods, from 23% to 55% and 81%, respectively. In the group of TEV in association 
with other anomalies, there was no significant change, the detection rate of TEV over the three 
time periods varied from 72% for the first period and 75% and 73%, respectively. Isolated 
bilateral TEV cases were detected more than twice as often as isolated unilateral TEV. 
The three largest groups of associated anomalies were syndromes/sequences (26%), chromosome 
aberrations (26%) and musculoskeletal disorders (24%). All anomalies are listed in Table 2 
below. The undetected associated anomalies among fetuses with TEV are shown in Table 3. 
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Table 2. Developmental disorders/syndromes among 58 fetuses with bilateral or unilateral TEV 
and associated anomalies 
 
   
Developmental disorder n % 
Syndromes or Sequences 15 26 
Chromosome aberrations 15 26 
Musculoskeletal 14 24 
CNS including meningomyelocele 7 12 
Genitourinary 3 5 
Cardiovascular 2 3 
Other 2 3 
Total 58 100 
 
 
Table 3. Prenatally undiagnosed associated anomalies among fetuses with TEV 
 
 
 
Fifteen of 113 (13%) cases with TEV had chromosome aberrations and 13 of these 15 had 
structural anomalies in addition to the TEV that led to karyotyping. The two other fetuses with 
chromosome aberrations presented with no other abnormality than TEV, detected by ultrasound. 
One fetus was karyoptyped and had 47 XYY. The pregnancy was continued. The other fetus was 
not karyotyped and a child with trisomy 21 was delivered. Fetuses with chromosome aberrations, 
with no structural anomalies other than TEV correspond to 1.8 % of the total TEV population or 
3.6% of the assumed isolated TEV population. 
Main diagnosis made postnatally TEV detected prenatally n 
Trisomy 21 Yes 1 
Charcot-Marie-Tooth Disease  Yes 1 
Anisomely, Smith-Lemli-Opitz Syndrome Yes 1 
Torticollis  Yes 1 
Congenital hip dislocation Yes 1 
Kyphomelic dysplasia No 1 
Pulmonary stenosis No 2 
Congenital hip dislocation No 1 
Rectum atresia, unilateral missing foot below ankle joint No 1 
Total  10 
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Pregnancies were terminated in 23% of the cases, all with severe additional anomalies. Treatment 
of TEV included surgery in 86% of the cases. 
 
 
Comments 
 
The overall detection rate for TEV improved significantly over time, most likely a consequence 
of improved equipment and sonographer experience during the 18-year period. The prenatal 
detection increased when TEV was bilateral, which might indicate that once a normal foot was 
seen, a scan of the contra lateral foot received less attention. This is supported by the fact that 
when other associated anomalies were present there was no difference in the detection of 
unilateral or bilateral TEV; this indicated that, the fetuses then were more carefully scanned for 
further anomalies. 
 
Our study showed that in a small number among fetuses with TEV (Table 3), associated 
chromosome aberrations or severe syndromes were not diagnosed until after delivery. We 
therefore suggest that karyotyping should always be offered when isolated TEV is found. In a 
counseling situation, parents should be provided with information about possible underlying 
syndromes and neurodevelopmental conditions that may not be ruled out. Additionally, parents 
should also be informed that in suspected isolated TEV associated anomalies might remain 
undetected prenatally. The counseling may also include the information that the postnatal 
treatment is easily performed with good results based on the Ponseti method that is used 
worldwide. 
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Paper 2 
Prenatal ultrasound detection of facial clefts: 
a prospective study of 49 314 deliveries in a non-selected population in Norway 
 
Results 
 
A total of 101 fetuses or newborns with facial clefts were registered. The distribution of clefts 
was: 25 (25%) cleft lip, 52 (51%) cleft lip and palate and 24 (24%) cleft palate. No cleft palate 
was detected prenatally in the whole 18-year period. Cleft lip with or without cleft palate (CL(P)) 
was detected prenatally in 35/77 (45%) of the cases, with a significant increase in the detection 
rate (P = 0.03) from 14/41 (34%) to 21/36 (58%) between the two nine-year periods, respectively. 
The median gestational time of detection of CL(P) was 19+2 weeks for the total period, with no 
change over time. Altogether, 24/35 (69%) were detected at a second trimester routine ultrasound 
examination. Thirty-three of 77 (43%) CL(P) and 14/24 (58%) of CP had associated anomalies. 
When the condition subdivided for CL(P) associated with other anomalies, the detection rate 
increased from 44% to 63% and the rate for isolated CL(P) increased from 26% to 53% in the 
two time periods. There was a higher detection rate for bilateral CL(P), 16/26 (62%) than for 
unilateral CL(P), 19/49 (39%). 
 
Among all 101 fetuses with facial clefts, 47/101 (47%) had associated anomalies, including 
chromosome aberrations, with a distribution of 33/77 (43%) of the CL(P) and 14/24 (58%) of the 
CP, as shown in Table 4. 
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Table 4 Distribution of facial clefts 
 CL(P) CP 
 n % *TOP/IUFD *Death 
pp 
n % TOP *Death 
pp 
Isolated 44 57   10 42   
Associated 33 43   14 58   
Chromosome      
aberrations 
8 10 6/1 1 4 17 1 1 
Syndromes/ 
sequences 
9 12 2/0  9 38 3  
Structural anomalies 
without chromosome 
aberrations/ 
syndromes/sequences 
16 21 1/1 1 1 4   
Total 77 100 9/2 2 24 100 4 1 
*TOP/IUFD = Termination of pregnancy/ Intrauterine fetal death 
*Death pp = Death within 6 months post partum 
 
 
Twelve/101 (12%) of all fetuses with clefts had chromosomal aberrations. Nine of these 12 had 
prenatal ultrasound findings that led to karyotyping. In the remaining three cases, the 
chromosome diagnosis was made postnatally. The first was a trisomy 13 with undetected bilateral 
CL(P), atrial septal defect, dilated urether, microphthalmus, low set ears and a hypoplastic pelvis; 
the second case was an undetected Klinefelter 49 XXXXY with postnatal diagnosis of cleft 
palate, clinodactyly in fingers and toes, general stiffness of the joints, dysmorphic face features, 
micro penis and bifid scrotum; the third fetus without prenatal remarks had a deletion of 
chromosome p4 and presented with growth retardation, cleft palate, hypertelorism, short sternum, 
clinodactyly, retentio testis and micropenis. In 18/101 (18%) cases, the facial clefts were part of a 
syndrome (13/101) or sequence (5/101) without chromosome aberrations. 
 
Among the 42 fetuses with CL(P) not detected prenatally, 25/42 (62%) CL(P) were isolated cases 
and 17/42 (46%) had associated anomalies. Of the prenatally undetected CLP with associated 
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anomalies,è there was one fetus with acrania, the pregnancy was terminated. The remaining 
associated cases were not diagnosed before birth and were as following: one trisomy 13, two 
Median cleft syndromes, one Silver Russell Syndrome, two heart failures (one Uhls syndrome, 
one ASD secundum), the remaining had finger and foot deformities. 
 
Termination of pregnancy was performed in 13/101 (13%) of the cases of CL(P) and CP. 
Termination was not performed in cases with an isolated diagnosis of CL(P); it was performed 
when severe additional anomalies were present. 
 
 
Comments 
 
The breakdown according to type of cleft (cleft lip, cleft lip and palate, cleft palate) is in 
accordance with the thorough study by Gorlin that described CLP as comprising about 50% of 
the cases, with cleft lip and isolated cleft palate each comprising about 25% (Gorlin et al. 1971). 
Our other findings were also similar according to the literature when relating to gender, with a 
male to female ratio of 1.9 to 1 in the group cleft lip and palate and to the predominant affection 
of the left side when the cleft was unilateral.  
 
Our average detection rate of 45% for CL/P was relatively high and increased over time. Surveys 
conducted at several centers have reported detection rates of CL(P) between 18% and 22% 
(Grandjean et al. 1998; Stoll et al. 2000; Shaikh et al. 2001). Stoll showed that the prenatal 
detection of isolated CL(P) was 27% in the period of 1989-1998, and that the detection rate of 
CL(P) with associated anomalies was 50% for the same time period (Stoll et al. 2000). Studies 
from other centers showed detection rates from 22% to 65%, (Chitty et al. 1991; Hafner et al. 
60 
1997; Boyd et al. 1998; Cash et al. 2001), but these studies all had small numbers of patients. The 
highest detection rate was published by Bronshtein who reported a detection rate of 92% (11/12) 
(Bronshtein et al. 1994). 
 
Facial clefts are mostly a cosmetic challenge, and a correctable anomaly when other anomalies 
are absent. Nevertheless the study demonstrated that about one half of the fetuses/newborns with 
facial clefts had associated anomalies; 12% of all cases had chromosome aberrations and 18% of 
cases were part of a syndrome or sequence. Therefore, accurate examination of the fetal face is 
important and karyotyping should be offered in all cases where facial clefts are suspected, since 
chromosome aberrations cannot be excluded completely. Parents should be provided with 
information about possible underlying conditions. 
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Paper 3 
Prenatal detection of trisomy 21 by second trimester ultrasound examination and maternal 
age in a non-selected population of 49 314 births in Norway 
 
Results 
 
Eighty-eight cases of trisomy 21 were registered during a time period of 18 years, between 1987-
2004. The total prevalence of trisomy 21 in the non-selected population, including all prenatally 
and postnatally diagnosed cases, was 1.78 per 1000 births (95% confidence interval 1.4 - 2.2). 
The prevalence of live born trisomy 21 infants (excluding termination of pregnancies and IUFD) 
was 1.14 per 1000 births (95% confidence interval 0.86 - 1.47).  
 
The total prenatal detection rate was 43% (38/88). There was no significant change (P = 0.3) in 
detection rate observed within the three time periods that were studied. Fourteen percent (12/88) 
were detected by amniocentesis due to advanced maternal age, and 29% (26/88) by prenatal 
ultrasound (2/26 in first trimester, 22/26 in second trimester and 2/26 in third trimester). Seventy-
two percent (63/88) of all women with a trisomy 21 fetus were under 38 years of age. The 
percentage of women > 38 years opting for karyotyping during the 3 time periods decreased 
significantly from 51% to 50% and 36%, respectively. The average termination rate of trisomy 21 
fetuses was 84%, with no significant change over time. An outline of all the detected and non-
detected cases are shown in Figure 5. 
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Figure 5. Outline of all detected and undetected trisomy 21 cases in the non-selected population 
of 49 314 births 
(TOP, termination of pregnancy; IUFD, intrauterine fetal death) 
 
 
Among the 56 newborns with trisomy 21, 6 cases were diagnosed prenatally. Consequently 50 
cases were diagnosed postnatally, with structural anomalies found in 43/56 (77 %) of the 
newborns. The anomalies are listed in Table 5. 
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Table 5. Structural anomalies found postnatally among all 50 cases with undetected trisomy 21 
Anomalies n % 
Atrial septal defects (ASD) 9 18 
Ventricular septal defects (VSD) ∗ 11 22 
Atrioventricular septal defect (AVSD) 6 12 
Double outlet right ventricle (DORV) 1 2 
Tetralogy of Fallot (TOF) 1 2 
Pulmonary artery stenosis 1 2 
Imperforate anus 2 4 
Syndactyly between 3rd and 4th finger 1 2 
Total  32 64 
∗ 3 of 11 VSD’s required surgery postnatally 
 
Twenty-six of the 56 (46%) newborns needed one or more surgical treatments. During the last 
six-year period from 1999 to 2004 we have complete electronic data registration of hospital 
visits. In this period the median number of contacts with the outpatient clinic per child with 
trisomy 21 was 16 times during the first year of life and 10 times during the second year of life. 
The median number of hospitalization days per child was 18 for the first year (range 4-53 days) 
and median 2 days for the second year excluding hospitalizations for cardiac surgery, which is 
centralized to the National Hospital in Oslo.  
 
Comments 
 
During the 18-year study period there was no change in the maternal care program which 
provided one second trimester routine ultrasound examination to each pregnant woman. Only 
women with a maternal age of 38 years or more at term and a few other indications had the right 
to have an amniocentesis. In the second part of 2004, a first-trimester ultrasound examination was 
offered to these women, but without biochemistry.  
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Since a maternal biochemistry program for the detection of trisomy 21 was not available during 
the study period, it was possible to study the efficacy of routine ultrasound and karyotyping in 
women over the age of 38, in the detection of trisomy 21. The overall detection rate for trisomy 
21 was as low as 43%, without increase during the whole 18-year study period. In our non-
selected population, most cases were detected by ultrasound (29%). Karyotyping due to maternal 
age contributed only 14% of the detected cases. Karyotyping due to maternal age was offered to 
women aged 38 years and over, but this comprised only 3.7% of the whole non-selected 
population, for the whole 18-year period. In addition, the rate of women accepting the offer 
diminished significantly during the 18-year study period from 51% and 50% to 36%, 
respectively. This may show that women in general are skeptical to amniocentesis and decline the 
offer of karyotyping if the risk based on maternal age and ultrasound is relatively low.  
 
As a consequence of the “Law of Biotechnology” which was introduced in 2004 (LOV-2003-12-
05-100. 2003), women who qualify for fetal genetic testing are now offered an ultrasound scan 
and in addition a hormone screening test (PAPP A and free β-hCG) instead of karyotyping by 
amniocentesis. If the total risk for trisomy 21 is relatively low, they may elect to decline the 
offered amniocentesis. Our results showed that 72% of all trisomy 21 fetuses were born to 
women below 38 years, underscoring the inefficiency of screening for trisomy 21 on the basis of 
age. The debate in Norway now focuses on the fact that women below 38 years also may have the 
combined non-invasive tests to assess their individual risk. 
 
Our study shows that if the aim is to detect trisomy 21, a program based on the maternal age is 
obsolete since the majority of trisomy 21 cases are born to mothers younger than 38 years. Our 
study also shows that the routine fetal examination offered at 18 weeks is a poor test to detect 
trisomy 21, since only fetuses with associated anomalies may be detected. Comparison with other 
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published studies is difficult since most women in the other studies either have had a second-
trimester biochemistry test included in the maternal care program or have been offered first-
trimester ultrasound screening, or have had a possibility for first-trimester scan in private 
practice. 
 
In our study, the termination rate of trisomy 21 fetuses was 84%, with no significant change over 
time. A systematic review, including studies from different countries such as the USA, UK and 
Europe, showed that the corresponding termination rate for trisomy 21 was approximately 92% 
(Mansfield et al. 1999). This indicates that the attitude of Norwegian women towards termination 
of pregnancy once the diagnosis of trisomy 21 is made, is more conservative than in other 
industrialized countries. In spite of this, there are reasons to believe that also Norwegian women 
now are interested in the option of an early testing. 
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Paper 4 
Termination of pregnancy following ultrasound examination in a non-selected population of 
41 382 deliveries in Norway: trends over a 15-year period  
 
Results 
 
Termination of pregnancy was performed in 163 fetuses. There was an increase in the detection 
rate of anomalies across the three periods, and a significant trend towards earlier detection of fetal 
anomalies during the fifteen years with a median of 18+0 weeks. The rate of termination of all 
prenatally detected anomalies was 29.7% (163/548) for the total study period. Analysis of the 
three five-year periods separately showed a slight, but significant decrease in the termination rate 
(P = 0.039). An overview of the detected anomalies and the terminations thereof is given in Table 
6. Furthermore, Table 7 shows an overview over the subgroups of anomalies that led to 
termination. The two largest groups with nearly 1/3 of all cases in each were the groups of 
chromosome aberrations and central nervous system anomalies. In the group of chromosome 
aberrations there were 38% trisomy 21, 34% trisomy 18, and the rest were trisomy 13 and others. 
 
Twenty-one percent (34/163) of the anomalies were detected before the routine scan, 79% 
(128/163) were detected at the routine scan, and 1/163 after the routine scan, a trisomy 18 was 
diagnosed at 26+2 weeks of gestation. There was not a significant change in prognostic 
categories during the three time periods, so the severity of the detected anomalies remained 
constant. The average median prognostic score was 2.2 for the first time period and 2.3 for the 
second and third time periods, respectively, with no shift in tendency to terminate less severe 
conditions over time.  
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Table 6. Overview of all deliveries, detected anomalies and terminations in the study periods 
 
  
Deliveries 
 
Anomalies among total deliveries 
 
TOP of total anomalies 
Periods N n % n % 
Period 1 
(1987- 1991) 
13 817 153 1.1 48 31.4 
Period 2 
(1992- 1996) 
14 087 181 1.3 64 35.4 
Period 3 
(1997- 2001) 
13 478 214 1.6 51 23.8  
Total 41 382 548 1.3 163 29.7 
TOP, termination of pregnancy 
 
 
Table 7. Anomalies listed in subgroups that led to termination of pregnancy (TOP) for the total 
period and the three time periods 
 
 
Total period 
(1987-2001) 
Period 1 
(1987-1991) 
Period 2 
(1992-1996) 
Period 3 
(1997-2001) 
Anomalies N % n % n % n % 
Chromosome aberrations 53 33 16  33 23 36 14 27 
Central nervous system anomalies 49 30 13  27 21 33 15 29 
Skeletal anomalies 16 10 7  15  7 11 2 4 
Urinary system anomalies 12 7 4 8.5 2 3 6 12 
Syndromes, associations 11 7 3 6 3 5 5 10 
Congenital heart defects 7 4 1 2 4 6 2 4 
Other severe defects 15 9 4 8 4 6 7 14 
Total  163 100 48 100 64 100 51 100 
 
 
There was no significant change in prognostic categories during the three time periods. The rate 
of termination of fetuses in the prognostic categories 1-5, which all were lethal or would lead to 
severe disability, was 90% in the first period, 94% and 82%, in the second and third periods 
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respectively. The median prognostic category for the three five-year periods was 2.2, 2.3 and 
2.3, respectively, with no significant change within the time periods. The diagnoses of 
fetuses with a category higher than 5 are listed in Table 5 in Paper 4. 
 
During the total study period, 8% (42/548) of the fetuses with prenatally detected very severe 
and/or lethal congenital anomalies were not terminated and died in-utero, during delivery or 
within 3 months after delivery. Seven of 42 fetuses in the group that continued the pregnancy 
with severe anomalies were twins, all with a healthy co-twin. The median time of detection in the 
three five-year periods were: 30+3, 19+1 and 18+1 gestational weeks, respectively. Intrauterine 
death affected 48% (20/42) of these fetuses at median of 18+5 gestational weeks (range 13-34 
weeks), 52% (22/42) infants died intra partum or within 3 months after delivery with median 1.5 
days of survival (range 0-91 days). The longest survivor was born with hypoplastic left heart 
syndrome. The infant died after 91 days following cardiac surgical interventions. There was no 
significant change in the number of continued pregnancies with prenatally diagnosed severe fetal 
anomalies, for either the total or for the separate time periods. 
 
The median prognostic category for the anomalies found by ultrasound, which later resulted in 
either IUFD or death intra partum and up to 3 months after delivery, was 1.1 for the first period, 
and 2.2 for the second and third periods, respectively. 
 
 
Comments 
 
There was no increase in the rate of termination of pregnancies during the study period, although 
the detection rate of malformations increased. In fact, the termination rate decreased significantly 
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during the three five- year periods. This is similar to other studies where no change was found in 
patients’ decisions over time (Evans et al. 1996), but still in contrast to several studies which over 
time have seen an increase in termination rates (Boyd et al. 1998; Stoll et al. 2002; Guillem et al. 
2003; Rankin et al. 2005; Richmond and Atkins 2005). Nevertheless, a mean termination rate of 
29.7% in our population is far lower than large published register studies that report termination 
rates of 57-83% of non- chromosomal anomalies (Liu et al. 2002; Neilson 2004; Garne et al. 
2005).  
In our study, the prognostic categories for terminated pregnancies were stable for the total period 
of 15 years (see prognostic categories Table 1, page 51). There was no trend towards termination 
of pregnancy for less severe indications over time. This is also in contrast to studies were there 
was an increase in termination of pregnancy thought to be due to an increase in the sensitivity of 
detection of anomalies, and to a widening of indications (Guillem et al. 2003).  
 
An important finding of the study was a significant earlier detection of anomalies in the last two 
time periods. This applies to the group that terminated the pregnancy as well as to the group who 
continued their pregnancy. Although the gestational age at detection decreased, there was no 
increase in the termination rate. This is of particular interest regarding the group of women who 
continued their pregnancy. During the time periods 2 and 3 they did have the option of 
terminating their pregnancies, as opposed to the first 5-year period when the median gestational 
week of detection was 30+3. Still they chose to continue. These women were well informed 
about the severity of the anomaly of their fetus. Only a minority of the pregnancies were twin 
pregnancies, the majority were single fetuses with severe diagnosis. 
 
In conclusion, this study clearly indicates that it has been possible to introduce a routine offer of 
an ultrasound examination and fetal medicine in Norway in such a way that the feared 
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development including an increase in the abortion rate caused by the identification of anomalies 
has not taken place. A liberalization of the indications for abortions over time has not happened 
either. On the contrary, our unit, the largest tertiary fetal medical unit in Norway, has managed 
the termination policy in a way which we believe will be accepted by Norwegian society in 
general, and which respects the autonomy of women. That policy most likely is a result of the 
experts dealing with the diagnosis of anomalies and being supported by our center’s 
multidisciplinary perinatal team, which helps to give realistic information on treatment and 
prognosis of the respective anomalies. Such a team certainly aids parents in gaining 
understanding and security to make a decision they are comfortable with.
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SUMMARY 
Background 
 
In Norway a second trimester routine fetal ultrasound examination around 18 gestational weeks 
was introduced in 1986. One of the additional aims, in addition to an improved estimation of the 
gestational age, detection of placenta and detection of multiple pregnancies, was to systemically 
examine the fetal anatomy. If fetal anomalies are found it usually implies major consequences for 
the management of the pregnancy and the neonatal period. In some cases the findings can lead to 
the wish to terminate the pregnancy. Advances in ultrasound technology and improvements in the 
skills of the sonographers have also resulted in an increased detection rate of malformations. 
 
 
Aims of the studies 
 
The aim was to study some rather minor anomalies that might also be associated with severe 
anomalies including chromosome aberrations. The diagnosis of trisomy 21 on a population basis 
was also studied. Further, a major aim was to evaluate the consequences of routine ultrasound at 
18 weeks regarding termination of pregnancy over the time span of fifteen years. 
 
 
Material and Methods 
 
Prospective follow-up studies were carried out in a non-selected Norwegian population from 
1987 to 2004 including a total of 49 314 births (papers 1-3). In paper 4 the study period was from 
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1987 to 2001 including a total of 41 382 births. Data of all specimens that underwent termination 
of pregnancy were registered. All specimens with trisomy 21, either detected by prenatal 
ultrasound or amniocentesis due to maternal age, or after delivery, were registered. The same 
prospective study was performed for fetuses with talipes equinovarus and with cleft-lip-palate. 
The study periods were all divided into time periods, to look for changes in detection rates. 
 
 
Results 
 
Talipes equinovarus 
One hundred and thirteen cases of TEV were registered during the 18-year period, 49% had 
isolated TEV, 51% had associated anomalies. During the 3 six-year periods, there was a 
significant improvement (P = 0.006) in the overall detection of TEV. The three largest groups of 
associated anomalies were syndromes/sequences (26%), chromosome aberrations (26%), and 
musculoskeletal disorders (24%).  
Our study showed that in a small number of suspected isolated TEV, associated chromosome 
aberrations or severe syndromes were not diagnosed until after delivery. Pregnancies were 
terminated in 23% of the cases, all with severe additional anomalies. Treatment of TEV included 
surgery in 86% of the cases. 
 
 
Facial clefts 
A total of 101 fetuses or newborns with facial clefts were registered. The distribution of clefts 
was: 25 (25%) cleft lip, 52 (51%) cleft lip and palate and 24 (24%) cleft palate. No cleft palate 
was detected prenatally. Cleft lip with or without cleft palate (CL(P)) was detected prenatally in 
35/77 (45%) of the cases, with a significant increase in the detection rate (P = 0.03) 34% to 58% 
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between the two nine-year periods, respectively. Thirty-three of 77 (43%) CL(P) and 14/24 
(58%) of CP had associated anomalies. Twelve/101 cases (12%) had chromosomal aberrations. In 
18/101 (18%), the clefts were part of a syndrome or sequence.  
 
 
Trisomy 21 
Eighty-eight cases of trisomy 21 were registered. The prenatal detection rate was 43% (38/88). 
No significant change in the detection rate was observed over the 18 years. Fourteen percent 
(12/88) were detected by amniocentesis due to advanced maternal age and 29% (26/88) by 
prenatal ultrasound. Seventy-two percent (63/88) of all women with a trisomy 21 fetus were 
under 38 years of age. The termination rate of trisomy 21 fetuses was 84%, with no significant 
change over time. 
 
 
 
Termination of pregnancy 
Termination of pregnancy was performed in 163 fetuses. There was an increased detection rate of 
anomalies within the three periods, and a significant trend towards earlier detection of fetal 
anomalies during the fifteen years with a median of 18+0 weeks. Nevertheless there was a 
significant decrease in termination rate over time (P < 0.039). There was no shift in tendency to 
terminate less severe conditions over time. The termination rate of fetuses which had a lethal 
condition or which would lead to the most severe disabilities, was 90% in the first period, 94% 
and 82% in the second and third periods respectively. 
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Conclusions and future aspects 
 
In the study on talipes equinovarus as well as on facial clefts, it was of interest to study specific 
anomalies which may be harmless and have good prognosis when occurring isolated, but which 
also could be associated with very severe anomalies that may be difficult to diagnose 
anatomically. These cases obviously have a completely different and very severe prognosis. 
Parents should be informed that in suspected isolated CL(P) or talipes equinovarus associated 
anomalies might remain undetected prenatally, and we therefore suggest that karyotyping should 
always be offered all patients when a facial cleft or TEV is diagnosed. 
 
In the study on trisomy 21 fetuses it was shown that the Norwegian maternal care program with 
only one second-trimester ultrasound examination for all pregnant women below 38 years, 
resulted in a detection rate of less than 30% for trisomy 21. Many of the live-born trisomy 21 
children had congenital anomalies, but not all were easily detectable. Soft markers of trisomy 21 
are most easily found during a first trimester ultrasound examination, which was not included in 
the health care program during the study period. The study showed that a program based on 
maternal age to detect trisomy 21 has little effect. Ultrasound at 18 weeks also is a poor test to 
detect trisomy 21. 
 
We found that termination rates were stable throughout the 15-year study period. The prognostic 
score for terminated fetuses remained stable. This clearly indicates that it has been possible to 
introduce a routine offer of an ultrasound examination and fetal medicine in Norway in such a 
way that the increase in the abortion rate amongst the located anomalies has not taken place. 
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A liberalization of the indications for abortions over time has not taken place either. That policy 
most likely is a result of the experts dealing with the diagnosis of anomalies and being supported 
by our center’s multidisciplinary perinatal team, which helps to give realistic information on 
treatment and prognosis of the respective anomalies. It is most important that a multidisciplinary 
counseling team is able to give as correct and neutral counseling as possible, being both objective 
and supportive. Such a team ensures that parents gain the necessary understanding and security to 
make a decision they are comfortable with.  
 
Approaching the anomaly of the fetus in a realistic way is the only fair way – so parents can get a 
perspective on how life will be if they choose to continue the pregnancy. The long-term prognosis 
is an important part of this information.At the same time, it is important to get reassuring 
counseling when minor anomalies are found. 
 
It is interesting to note that not only medical experts take part in the discussion of prenatal 
detection of anomalies. It is a topic that interests most people. “Everybody” has an opinion about 
ethics in prenatal medicine and especially regarding termination of pregnancy. 
 
For parents it is important to have scans, have a look at the baby, and establish a relationship with 
their unborn fetus. If this includes getting a diagnosis, parents want to know as much as possible 
about their fetus. It is therefore reassuring that the ultrasound detection rates of structural 
anomalies is increasing over time. Nevertheless, the detection of chromosomal aberrations might 
in the future be diagnosed mainly with the help of blood samples in early pregnancy. Research is 
ongoing with specific serum biochemistry (Laigaard et al. 2006; Christiansen et al. 2007) as well 
as with fetal DNA testing (Dhallan et al. 2007). 
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The aim for the future must be to further increase detection rates. A correct, detailed prenatal 
diagnosis with exclusion of associated anomalies will be a major task also in the future. If 
anomalies are found, it will be of great importance in giving correct and reassuring counseling to 
the parents, to help them to be secure in their understanding of the diagnosis and the 
consequences of either continuing the pregnancy or terminating it. 
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